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Abstract The activation of peroxisome proliferator-activated
receptor Q (PPARQ) has been shown to inhibit the production and
the effects of proinflammatory cytokines. Since interleukin-1L
(IL-1L) directly mediates cartilage degradation in osteoarthritis,
we investigated the capability of PPARQ ligands to modulate IL-
1L effects on human chondrocytes. RT-PCR and Western blot
analysis revealed that PPARQ expression was decreased by IL-
1L. 15-Deoxy-v12;14-prostaglandin J2 (15d-PGJ2), in contrast to
troglitazone, was highly potent to counteract IL-1L-induced
cyclooxygenase-2 and inductible nitric oxide synthase expres-
sion, NO production and the decrease in proteoglycan synthesis.
Western blot and gel-shift analyses demonstrated that 15d-PGJ2
inhibited NF-UB activation, while troglitazone was ineffective.
Although 15d-PGJ2 attenuated activator protein-1 binding on
the DNA, it potentiated c-jun migration in the nucleus. The
absence or the low effect of troglitazone suggests that 15d-PGJ2
action in human chondrocytes is mainly PPARQ-indepen-
dent. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Progressive destruction of articular cartilage is a common
feature of rheumatoid arthritis and osteoarthritis. It is largely
accepted that interleukin-1 (IL-1) initiates a number of events
which lead to the inhibition of the synthesis of the extracellu-
lar matrix components and promotes their degradation [1^3].
Thus, cellular responses to IL-1 within the joint may consti-
tute potential targets for disease intervention.
Peroxisome proliferator-activated receptor-Q (PPARQ) be-
longs to the superfamily of nuclear receptors which are li-
gand-activated transcription factors. They regulate gene ex-
pression by binding with their heterodimeric partner,
retinoid X receptor to speci¢c response elements located in
the promoter of target genes. These genes are mainly involved
in lipid metabolism, glucose homeostasis regulation and in cell
di¡erentiation [4^6]. Besides these functions, this nuclear re-
ceptor has been shown to play an important role in the con-
trol of in£ammatory processes. The possibility to modulate
cell activation by the use of PPARQ ligands has been demon-
strated in many cell types, including aortic smooth muscle
cells [7], monocytes and macrophages [8^10], astrocytes and
glial cells [11,12], T lymphocytes [13], vascular endothelial
cells [14] or in animal models [15]. However, to date, this
receptor has been poorly studied in cartilage.
The modulation of the e¡ects of IL-1L is of great interest
for the protection of cartilage in arthritic diseases. We recently
described the presence of PPARK and PPARQ in rat cartilage,
and we found that 15-deoxy-v12;14-prostaglandin J2 (15d-
PGJ2), a PPARQ ligand, modulated the IL-1L-induced de-
crease in proteoglycan (PG) synthesis [16].
The aim of the present work was to investigate the possi-
bility to counteract IL-1L e¡ects in human chondrocyte cul-
tures by the use of PPARQ ligands, and to study the inhibitory
e¡ects on the activator protein-1 (AP-1) and nuclear factor-UB
(NF-UB) transcriptional pathways. Controversy exists about
the identi¢cation of intracellular targets involved in the mech-
anism of action of cyclopentenone, and especially of 15d-PGJ2
[17]. Some of its e¡ects have been shown to be through the
transcriptional inhibition exerted by activated PPARQ [8^10].
However, other works, which take into account the lack of
e¡ect of synthetic PPARQ ligands, suggest a main contribution
of PPARQ-independent mechanisms on the anti-in£ammatory
e¡ect of 15d-PGJ2 [11,17^19]. No data is available concerning
the mechanism of action of cyclopentenone prostaglandins in
cartilage cells.
In the present study, we demonstrate that 15d-PGJ2 was
much more potent than troglitazone to counteract the de-
crease in PG synthesis and the expression of inductible nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in-
duced by IL-1L. We also found that this prostaglandin exerts
its e¡ects at least partly by antagonizing the activation of AP-
1, and especially NF-UB pathways. These results, and espe-
cially the much lower e¡ect of troglitazone, strongly suggest
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that the main e¡ects of 15d-PGJ2 in human chondrocytes are
PPARQ-independent.
2. Materials and methods
2.1. Chondrocyte isolation and culture
Articular cartilage was obtained after routine joint surgery from
informated donors who had undergone hip replacement due to frac-
ture. Cartilage specimens were examined thoroughly, both macro-
scopically and microscopically. Only those with neither lesions nor
alterations were further processed. Slices of cartilage were aseptically
dissected and chondrocytes were obtained by sequential digestions
with Pronase and collagenase B (Roche Molecular Biochemicals,
Meylan, France) as previously described [20]. Cells were cultured to
con£uence at 37‡C in a humidi¢ed atmosphere containing 5% CO2, in
complete medium [Dulbecco’s modi¢ed Eagle’s medium/Ham’s F12
supplemented with L-glutamine (2 mM), gentamicin (50 Wg ml31)
and 10% fetal calf serum (FCS)]. All experiments were performed
with primary or ¢rst passage chondrocytes to avoid any problems
of de-di¡erentiation. For the PG synthesis studies, chondrocytes
were also encapsulated in alginate beads (1.2%, w/v) (from Macro-
cystis pyrifera, Sigma, St. Quentin Fallavier, France) and cultured in
three-dimensional matrix according to the method of Hau«selmann [21]
and modi¢ed by us [22].
2.2. Recombinant human IL-1L (rhIL-1L) treatments in the presence of
speci¢c ligands
Chondrocyte cultures were treated with rhIL-1L in the range of 0^
250 U ml31 for 14 h (PPARQ mRNA analysis) or with 50 U ml31 IL-
1L for 6 h (iNOS and COX-2 mRNA analysis). The ligands or the
vehicle (0.1% Me2SO in ¢nal concentration) were added to cells 4 h
before rhIL-1L. The ligands tested were troglitazone (10 WM) and 15d-
PGJ2 (10 WM) (France-Biochem, Meudon, France). At 1 WM, both
ligands were ine¡ective, and at 100 WM, they were highly toxic for the
cells.
2.3. RNA extraction and quantitative RT-PCR analysis
Total RNA was extracted from cell cultures by a single-step gua-
nidinium thiocyanate^phenol chloroform method using Trizol reagent
(Gibco BRL, Cergy-Pontoise, France). PPARQ, iNOS and COX-2
mRNA from human chondrocyte cultures were assayed using a quan-
titative multistandard RT-PCR method that takes advantage of both
interest gene and L-actin sequence conservation between human and
rat [23]. This method allowed us to normalize the amount of the gene
mRNA to be measured with respect to that of L-actin mRNA. For
each sample, human RNA was mixed with a constant amount of total
RNA prepared from rat chondrocyte cultures, which brought both
competitive rat L-actin and interest gene sequences, and thus acted
as a multistandard source. PCRs for each gene ampli¢cation were
undertaken with oligonucleotide primers that are able to hybridize
with human and rat sequences with the same e⁄ciency. For PPARQ
ampli¢cation, the direct primer extended from nucleotides 841 to 866
and the reverse primer from nucleotides 1364 to 1339, in accordance
with the human sequence (GenBank accession number U79012). For
iNOS ampli¢cation, the direct primer extended from nucleotides 1489
to 1512 and the reverse primer from nucleotides 1921 to 1897, in
accordance with the human sequence (GenBank accession number
L09210). For COX-2 ampli¢cation, the direct primer extended from
nucleotides 410 to 432 and the reverse primer from nucleotides 850 to
830, in accordance with the human sequence (GenBank accession
number M90100).
Each ampli¢cation product was then distinguished by restriction
site polymorphism between the two species. The bands were quanti-
tated after electrophoresis and analysis of ethidium bromide-stained
gels. Results are expressed as the ratio (genehuman/generat)U(L-actinrat/
L-actinhuman) in arbitrary units.
2.4. Protein analysis
Immunoblotting analysis of PPARQ was performed on human
chondrocytes treated or not with rhIL-1L at 250 U ml31 for 14 h.
Proteins were isolated from cells in lysis bu¡er (10 mM HEPES, 400
mM KCl, 1.5 mM MgCl2, 0.5% Igepal) containing a protease-inhib-
itor mixture (Roche). Cell lysates were centrifuged, and the superna-
tants were collected and subjected to Western blot analysis using an
anti-PPARQ antibody [24]. Immunoblotting analysis of p65 and c-jun
were performed on nuclear extracts of cells stimulated with IL-1L (50
U ml31) for 1 h after a pre-incubation of 4 h with the ligand or
Me2SO (0.1%). Nuclear extracts were obtained as described for elec-
trophoretic mobility shift assay (EMSA) experiments (see below). For
immunocytochemical analysis, chondrocyte layers were ¢xed in 3%
formaldehyde in phosphate-bu¡ered saline (PBS) for 10 min and per-
meabilized in methanol for 20 min at 4‡C. They were then exposed to
the primary anti-PPARQ antibody (diluted 1:2000) for 30 min at 37‡C.
Cells were washed twice and incubated with the secondary £uorescein-
conjugated antibody (diluted 1:100 in PBS) for 30 min at 37‡C. Cells
were then mounted in Vectashield medium and photographed with a
Polyvar microscope (Reichert-Jung, Vienna, Austria).
2.5. PG synthesis and quanti¢cation of nitrites
After 8 days of culture, chondrocytes cultured in alginate beads
were treated as described before. The culture medium was then col-
lected to measure the concentration of nitrites according to the meth-
od of Griess [25] using NaNO2 as standard. The beads were incubated
in medium containing only 1% FCS with 10 WCi ml31 radiolabeled
sodium sulfate (Na352 SO4) for 4 h at 37‡C. After six washes with 0.15
M NaCl, the alginate beads were solubilized in Soluene 350 overnight,
and the 35SO4-labeled PG content was measured by liquid scintillation
with a LKB 1214 counter (Wallac, France).
2.6. Preparation of nuclear extracts and EMSA
For EMSA experiments, nuclear proteins were isolated as described
before [26], after few modi¢cations. Brie£y, cells were scraped in a
lysis bu¡er [10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM dithiothreitol
(DTT)] containing a protease-inhibitor cocktail and 0.5% Igepal, and
were incubated for 15 min on ice. Nuclei were collected by centrifu-
gation at 2000Ug for 5 min at 4‡C and resuspended in 50 Wl of the
same bu¡er without Igepal and KCl, but with 420 mM NaCl. After a
30-min incubation on ice, nuclear debris were removed by centrifuga-
tion at 13 000Ug for 10 min at 4‡C, and the supernatants were col-
lected and stored at 380‡C before use.
The DNA sequences of the double-stranded oligonucleotide speci¢c
of NF-UB were 5P-GAT CCA GTT GAG GGG ACT TTC CCA
GGC G-3P and 5P-GAT CCG CCT GGG AAA GTC CCC TCA
ACT G-3P. Those speci¢c to AP-1 were 5P-GAT CCG CTT GAT
GAC TCA GCC GGA AG-3P and 5P-GAT CCT TCC GGC TGA
GTC ATC AAG CG-3P. Complementary strands were annealed and
double-stranded oligonucleotides were labeled with [32P]dCTP using
the Klenow fragment of DNA polymerase (Gibco BRL, Cergy-Pon-
toise, France). Five micrograms of nuclear proteins were incubated
for 10 min at 4‡C in a binding bu¡er (20 mM Tris^HCl, pH 7.9, 5 mM
MgCl2, 0.5 mM DTT, 0.5 mM EDTA and 20% glycerol) in the pres-
ence of 2 Wg of poly(dI-dC). The extracts were then incubated for
30 min at 4‡C with 10 000 cpm of 32P-labeled NF-UB or AP-1 probes.
The samples were loaded on a 5% native polyacrylamide gel, and run
in 0.5U TBE bu¡er. NF-UB- and AP-1- speci¢c bands were con¢rmed
by competition with a 100-fold excess of the respective unlabeled
probe, which resulted in no shifted band. For supershift experiments,
after the addition of the labelled probe, the extracts were incubated
for 30 min at 4‡C in the presence of the speci¢c antibody (anti-p65 or
anti-p50 for NF-UB; anti-c-fos or anti-c-jun for AP-1).
3. Results
3.1. PPARQ mRNA and protein expression in human
chondrocytes is decreased by IL-1L
RT-PCR followed by digestion with a speci¢c restriction
enzyme led to products of the expected size (524 bp for hu-
man uncut product, 291+208+24 bp for rat digested products;
Fig. 1A). These results, as well as those of the Western blot
analysis (Fig. 1B), indicate that PPARQ is constitutively ex-
pressed in human chondrocytes at both the mRNA and the
protein levels. An immunocytochemical analysis was further
performed on normal chondrocyte primary cultures in order
to investigate the intracellular localization of the transcription
factor. Fluorescence signals speci¢c of PPARQ were mainly
observed in nuclei (Fig. 1C), which is in accordance with their
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site of action. No signal was detected in nucleoles. A low
cytoplasmic localization was also observed.
Because IL-1L has a key role in the events leading to car-
tilage damage, we have investigated its e¡ects on the expres-
sion of PPARQ mRNA and protein. Chondrocyte cultures
were treated with IL-1L in the range of 0^250 U ml31 for
14 h. Fig. 1A shows that PPARQ mRNA expression was sig-
ni¢cantly decreased in a dose-dependent manner. A Western
blot analysis furthermore showed that the mRNA level encod-
ing PPARQ upon treatment with IL-1L (250 U ml31) could be
related to the variation of the corresponding protein (Fig. 1B).
Fig. 2. E¡ect of troglitazone and 15d-PGJ2 on IL-1L-induced iNOS
(A) and COX-2 (B) mRNA expression. Human chondrocytes were
cultured in 1% FCS-containing medium for 4 h, then in the pres-
ence of the ligands (troglitazone or 15d-PGJ2) before being stimu-
lated with 50 U ml31 IL-1L for 6 h. Total RNA was immediately
extracted for RT-PCR experiments. Results are expressed as relative
arbitrary units with a value of 100 for the IL-1L treatment. Results
represent mean values þ S.D. (n = 5; **P6 0.05).
Fig. 1. PPARQ is constitutively expressed in human chondrocyte cul-
tures and is down-regulated by IL-1L treatment. A: Electrophoretic
pro¢le of RT-PCR products for PPARQ after speci¢c ampli¢cation
of mRNA from a mixture of human and rat cells, which brought
both competitive rat L-actin and PPARQ sequences. Top: RT-PCR
products for PPARQ. mRNA was extracted from chondrocyte cul-
tures treated or not with increased concentrations of rhIL-1L. The
ampli¢cation products were distinguished by restriction site poly-
morphism between the two species. Bottom: PPARQ transcripts
were quanti¢ed as described in Section 2 using the L-actin from the
same cDNA pools as an internal control. B: Top: Western blot
analysis of PPARQ protein expression in cultured chondrocytes
treated or not with IL-1L (250 U ml31) for 14 h. Bottom: The in-
tensity of the bands was determined by densitometric analysis and
¢xed at 100% for the control. This result is the mean of three inde-
pendent experiments. C: Intracellular localization of PPARQ in cul-
tured chondrocytes. Immunocytochemical analysis of PPARQ expres-
sion in human osteoarthritis chondrocyte cultures was performed
using polyclonal anti-PPARQ antibody. PPARQ protein is mainly ob-
served in nuclei, but not in nucleoles, with a low cytoplasmic local-
ization (**P6 0.05).
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3.2. E¡ects of PPARQ ligands on IL-1L-induced iNOS and
COX-2 mRNA expression
We further investigated the capability of PPARQ ligands to
modulate the e¡ects of IL-1L on human chondrocyte cultures.
IL-1L is well known to induce the expression of in£ammatory
enzymes, such as iNOS and COX-2, and the associated pro-
duction of metabolites, such as NO and prostaglandin-E2. To
this end, chondrocyte cultures were treated with IL-1L (50 U
ml31) for 6 h in the presence or absence of ligands and
mRNA expression for iNOS and COX-2 was assessed. IL-
1L induced a strong expression of both iNOS and COX-2
mRNA, and we found that 15d-PGJ2 at 10 WM was highly
e⁄cient to inhibit the mRNA expression of both enzymes.
After 4 h of pre-incubation, it completely abolished iNOS
mRNA expression (Fig. 2A) and led to a 65% decrease in
COX-2 mRNA (Fig. 2B). In contrast to 15d-PGJ2, troglita-
zone, at 10 WM, was much less e¡ective because it only led to
a 18% reduction in IL-1L-induced iNOS mRNA expression
and did not modulate COX-2 mRNA. No e¡ect was observed
with 1 WM troglitazone, whereas 100 WM troglitazone was
highly toxic for the cells, as shown by a strong increase in
Fig. 3. E¡ect of PPARQ ligands on IL-1L-induced decrease in PG
synthesis (A) and NO release (B) in human chondrocytes. Chondro-
cytes were cultured in alginate beads at a concentration of 5U106
cells ml31. Beads were cultured in 1% FCS-containing medium for
12 h before the treatments. Cultures were incubated in the presence
of the ligands 4 h before the addition of IL-1L (50 U ml31) in the
medium, and the chondrocytes were stimulated for 24 h. PG synthe-
sis was assessed by incorporation of radiolabeled sodium sulfate for
4 h at 37‡C. NO production was determined spectrophotometrically
according to the Griess method. Results represent mean val-
ues þ S.D. (n = 5; **P6 0.05 versus control; P6 0.05 versus IL-1).
6
Fig. 4. E¡ect of troglitazone and 15d-PGJ2 on IL-1L-induced translocation of p65 and c-jun in the nucleus. Top: Western blot analysis of p65
(A) and c-jun (B) in chondrocyte nuclei after treatment of chondrocyte cultures with IL-1L (50 U ml31) in the presence or absence of PPARQ
ligands. Nuclear proteins were extracted and immunoblot analysis was performed with speci¢c antibodies. Bottom: the intensity of the bands
was determined by densitometric analysis. Quanti¢cations are the result of three independent experiments.
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the extracellular lactate dehydrogenase activity (data not
shown).
3.3. E¡ects of PPARQ ligands on IL-1L-induced PGs synthesis
decrease and NO production
The chondroprotective potentiality of PPARQ ligands was
thereafter tested on chondrocytes cultured in alginate beads
by measuring the PGs synthesis and the NO production.
Treatment of chondrocytes with IL-1L (50 U ml31) for 24 h
induced a 40% inhibition of radiolabeled sulfate incorporation
(Fig. 3A) and a signi¢cant increase in nitrite production (Fig.
3B). When chondrocyte cultures were pretreated with 10 WM
15d-PGJ2, a 50% restoration of the PGs synthesis was ob-
served, whereas no e¡ect was obtained with troglitazone at
10 WM (Fig. 3A). Moreover, 15d-PGJ2 completely abolished
the IL-1L-induced NO production, which is coherent with its
e¡ects on iNOS mRNA, whereas troglitazone led to a weaker
inhibition of NO release (334%; P6 0.05 versus IL-1,
Fig. 3B).
3.4. 15d-PGJ2 inhibits both NF-UB and AP-1 activation
pathways in IL-1L-treated chondrocytes
NF-UB and AP-1 are two important IL-1L-inducible tran-
scription factors that drive the expression of many genes in-
volved in in£ammation or in cartilage degradation, such as
iNOS, COX-2, IL-1L, tumor necrosis factor-K and metallo-
proteinases. To test if PPARQ ligands could antagonize NF-
UB or AP-1 activation pathways, chondrocytes were pre-incu-
bated for 4 h in the presence of 10 WM 15d-PGJ2 or 10 WM
troglitazone before being stimulated with IL-1L (50 U ml31)
for 1 h. Western blot and gel-shift analyses were performed on
nuclear extracts to visualize the translocation of p65 and c-jun
proteins in the nucleus and the binding of NF-UB and AP-1
on the DNA, respectively. Fig. 4A shows that 15d-PGJ2 led to
a strong decrease in IL-1L-induced p65 translocation in the
nucleus (348%). In contrast, 15d-PGJ2 was shown to poten-
tiate the e¡ects of IL-1L on the translocation of c-jun in the
nucleus (+114%) (Fig. 4B). For both proteins, no e¡ect was
observed after a pre-incubation with troglitazone at 10 WM.
Fig. 5. 15d-PGJ2, but not troglitazone, reduces IL-1L-induced NF-UB and AP-1 DNA binding activities in cultured human chondrocytes. Chon-
drocytes were cultured in 1% FCS-containing medium with 15d-PGJ2 (10 WM), troglitazone (10 WM) or vehicle (DMSO 0.1%) for 12 h and
subsequently treated with IL-1L (50 U ml31) for 1 h. Nuclear proteins were extracted and 5 Wg of each sample were subjected to EMSA using
NF-UB (A) or AP-1 (B) consensus site radiolabeled probes. Complexes were visualized by autoradiography. NS = non-speci¢c complex. 100-
fold concentrated unlabeled probe. C: EMSA ‘supershift’ assays identifying the subunit components for NF-UB and AP-1 dimers The experi-
ments were performed three times; representative results are shown.
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EMSA allowed us to visualize the IL-1L-induced binding of
NF-UB and AP-1 on oligonucleotide probes containing their
speci¢c response element (Fig. 5). After 4 h of pre-incubation,
15d-PGJ2 prevented NF-UB and AP-1 activation by IL-1L,
whereas troglitazone was ine¡ective in both cases. Incubation
of nuclear proteins with a 100-fold concentrated unlabeled
probe was performed to indicate the speci¢city of binding of
NF-UB or AP-1 to the DNA. Moreover, a pre-incubation in
the presence of speci¢c antibodies made it possible to identify
the components of the protein complex as being p65/p50 het-
erodimer for NF-UB and c-jun/c-fos for AP-1.
4. Discussion
Besides its key roles in energy metabolism and cell di¡er-
entiation, PPARQ has been shown to be involved in the anti-
in£ammatory action of speci¢c agonists. These e¡ects have
been observed in di¡erent in£ammatory models, such as in
a mouse model of colonic in£ammation [15], in a vascular
in£ammation model using smooth muscle cell cultures [7]
and in AL-stimulated microglial activation experiments [12].
These studies suggested that PPARQ ligands would be e⁄cient
for the treatment of Alzheimer’s disease, in£ammatory bowel
disease or atherosclerosis. Moreover, both PPARK and PPARQ
ligands have been reported to inhibit the production and the
e¡ects of proin£ammatory cytokines by monocytes/macro-
phages in vitro [8,9]. These data indicate that PPARK and/
or PPARQ could constitute potential targets in the ¢eld of
in£ammatory or degenerative arthropathies. However, the
PPARs have been poorly described in the context of arthritic
diseases [27], and especially in cartilage.
We have recently reported the constitutive expression of
PPARK and PPARQ in normal rat cartilage at both mRNA
and protein levels [16]. The aim of the present work was to
characterize PPARQ in human normal chondrocytes and to
evaluate the e¡ects of ligands on IL-1L-stimulated cells. The
action of the ligands was ¢rst tested on iNOS and COX-2
mRNA expression, two major enzymes expressed in chondro-
cytes after IL-1L treatment. Our results show that 15d-PGJ2 is
much more e⁄cient than troglitazone. It is worth noting that
15d-PGJ2 completely abolished IL-1L-induced iNOS mRNA
expression. In the same way, troglitazone only led to a slight
inhibition of NO production without any chondroprotective
e¡ect.
15d-PGJ2 is described as a ligand for PPARQ. However, the
absence or the low e¡ect of troglitazone in the present work
raises the question of the real involvement of the receptor in
the action of this prostaglandin in human chondrocytes. In
activated monocyte or macrophage cell lines, cyclopentenone
prostaglandins have been shown to modulate cellular activa-
tion through the transcriptional inhibition exerted via PPARQ
[8,9]. On the other side, the contribution of other PPARQ-
independent mechanisms on the anti-in£ammatory action of
15d-PGJ2 have been demonstrated, in part, because of the
lack of e¡ect of synthetic PPARQ ligands [11,17^19]. Thus,
other intracellular targets have been identi¢ed, especially in
the NF-UB signalling pathway. The most reported one is
I-UB kinase (IKK), which is inhibited by direct phosphoryla-
tion of its catalytic subunit, IKKL [18]. Other lines of evidence
suggested that the cyclopentenone ring system of 15d-PGJ2
could also directly inhibit the DNA binding activity of NF-
UB through direct alkylation of a cysteine residue located in
the DNA binding domain of the p65 subunit [19]. These two
mechanisms have been shown to act in combination to inhibit
transactivation of the NF-UB target gene COX-2 in HeLa cells
and RAW264.7 cells. It is well established that NF-UB and
AP-1 are two important IL-1L-inducible transcription factors
involved in the expression of many genes central to arthritic
diseases and cartilage degradation [28,29]. Our results clearly
show that 15d-PGJ2 signi¢cantly inhibited p65 translocation
in the nucleus, but was also very potent to inhibit DNA bind-
ing activity of NF-UB. In comparison, troglitazone was com-
pletely ine¡ective on both steps. Some papers suggested that
the involvement of PPARQ, in the action of 15d-PGJ2, varied
among di¡erent cell types. The lack of e¡ect of troglitazone in
the present work would suggest a PPARQ-independent mech-
anism of action of 15d-PGJ2, perhaps because the expression
level of the receptor in chondrocytes was too low [16]. How-
ever, the ine⁄ciency of troglitazone may also be attributed to
the decrease in PPARQ expression upon IL-1L stimulation. To
verify this hypothesis, we have measured the expression of
PPARQ in cells treated with IL-1 L in the presence of one of
the ligands. We found that both 15d-PGJ2 and troglitazone
restored the expression of the receptor at the level of control
cultures (data not shown). One must also take into account
the relative low potency of troglitazone as a PPARQ ligand.
Numerous other agonists have been recently identi¢ed as
being much more potent and selective towards PPARQ [30].
Concerning AP-1 activation, our results clearly show that
both ligands were ine¡ective to counteract c-jun translocation
in the nucleus, and 15d-PGJ2 was even shown to potentiate
IL-1L e¡ects. However, the DNA binding of AP-1 was re-
duced by 15d-PGJ2. These two opposite e¡ects on the AP-1
pathway in chondrocytes are somewhat surprising. In PPARQ-
negative HeLa cells, 15d-PGJ2 was shown to strengthen the
activating e¡ect of phorbol 12-tetradecanoate 13-acetate on
AP-1 [19]. This e¡ect was believed to be attributable to the
activity of 15d-PGJ2 to stimulate jun N-terminal kinase
(JNK). This would explain the results of the present work,
since p65 is phosphorylated by JNK in response to IL-1L. In
HeLa cells, 15d-PGJ2 was also shown to induce the phosphor-
ylation of cysteine residues located in the DNA binding do-
main of NF-UB subunits. The action of 15d-PGJ2 on the AP-1
signalling pathway has been much less studied and, to our
knowledge, such a mechanism has not been described. How-
ever, it could therefore explain the present observations.
In conclusion, the present work characterizes, for the ¢rst
time, the potentiality of PPARQ-ligands to modulate the IL-1L
e¡ects on human chondrocytes. By taking into account the
low e¡ects obtained with troglitazone, the action of the 15d-
PGJ2 in human chondrocytes seems to be mainly PPARQ-in-
dependent, via the inhibition of both NF-UB and AP-1 path-
ways.
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